文献速递腹部技术与安全CT

胰腺癌肝低密度灶双能CT 50-keV VMI与碘定量价值

Conspicuity and characterization of pre-selected hypodense hepatic lesions in pancreatic cancer patients: limited clinical value of dual-energy portal phase CT.
PubMed 文献 · Abdom Radiol (NY) · 2026-09-24

针对胰腺导管腺癌患者门脉期双能CT上预选的肝低密度灶,回顾性纳入86例患者181个病灶,由两名放射科医生比较混合图像与50-keV虚拟单能图像的主观显著性、诊断信心及特征分析,并以病理和/或影像为参考标准。结果显示50-keV图像提升客观对比噪声比,但未改善主观显著性、诊断信心或特征分析表现。

要点

  • 50-keV VMI提高转移灶客观CNR,但不提高阅片主观显著性
  • 碘定量在转移与囊肿间差异有统计学意义,但与良性非囊性病变重叠较大
  • 脂肪肝背景下50-keV VMI的CNR优势不明确,诊断信心一致性较低

核心结论

  • 50-keV虚拟单能图像提高客观对比噪声比,但未改善主观显著性、诊断信心或特征分析表现
  • 碘定量提供补充信息,但不能区分转移与良性非囊性病变

研究设计与样本

  • 病灶由住院医师预选,两名放射科医生独立评估混合图像与50-keV虚拟单能图像
  • 参考标准为组织病理学和/或影像学

关键影像表现/征象

  • 转移灶在50-keV VMI上的CNR高于混合图像,总体队列为9.9±5.7对8.5±5.3
  • ≤10mm病灶在50-keV VMI上的CNR高于混合图像,为9.5±5.1对8±4
  • 脂肪肝背景下50-keV VMI与混合图像的CNR差异无统计学意义
  • 转移灶碘定量高于囊肿,但与良性非囊性病变存在较大重叠

诊断标准与关键数值

  • 总体队列转移灶CNR:50-keV VMI 9.9±5.7对混合图像8.5±5.3,p<0.001
  • ≤10mm病灶CNR:50-keV VMI 9.5±5.1对混合图像8±4,p=0.003
  • 观察者间一致性总体良好/非常好,但脂肪肝背景下诊断信心k值为0.58/0.48

临床应用与阅片要点

  • 常规阅片中50-keV VMI不能替代主观显著性判断,可留作定量辅助手段
  • 肝低密度灶鉴别时碘定量对囊肿与转移有一定参考价值,但对良性非囊性病变需谨慎解释
  • 脂肪肝患者中50-keV VMI的优势受限,报告时应降低对该重建的预期

局限性

  • 回顾性单中心设计
  • 病灶由住院医师预选,可能存在选择偏倚
  • 脂肪肝亚组中诊断信心观察者间一致性仅为中等

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the impact of 50-keV virtual monoenergetic images (VMIs) and iodine metrics on conspicuity and characterization of hypodense hepatic lesions in pancreatic ductal adenocarcinoma (PDAC) patients undergoing dual-energy portal phase CT.

METHODS: Consecutive patients with hypodense hepatic lesions who underwent dual-energy portal phase CT between January and December 2025 were retrospectively identified. Lesions were pre-selected by a resident. Two radiologists independently evaluated blended and 50-keV VMIs for lesion conspicuity and confidence for metastasis using 5-point Likert scales. Contrast-to-noise ratio (CNR) and iodine metrics were calculated. Subjective scores and CNRs were compared using the Wilcoxon test. Diagnostic performance for characterization was assessed using histopathology and/or imaging as the reference standard. Iodine metrics were compared using non-parametric tests. Subgroup analyses included lesions ≤ 10 mm and those in steatotic livers.

RESULTS: 181 lesions in 86 patients were included (58% metastases). Interobserver agreement was good/very good, except for diagnostic confidence in steatotic livers (k = 0.58/0.48). No differences were found between image sets in subjective conspicuity, diagnostic confidence, or characterization performance. Metastases had higher CNR on 50-keV VMIs than on blended images in the overall cohort (9.9 ± 5.7 vs. 8.5 ± 5.3, p < 0.001) and for lesions ≤ 10 mm (9.5 ± 5.1 vs. 8 ± 4, p = 0.003), but not in steatotic livers. Iodine metrics were higher in metastases than in cysts, with substantial overlap with non-cystic benign lesions.

CONCLUSION: 50-keV VMIs improve objective conspicuity but not subjective conspicuity, diagnostic confidence, or characterization performance. Iodine metrics provide complementary information but cannot distinguish metastases from non-cystic benign lesions.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. De Robertis, Fiorese, Cardobi, et al. Conspicuity and characterization of pre-selected hypodense hepatic lesions in pancreatic cancer patients: limited clinical value of dual-energy portal phase CT. Abdom Radiol (NY). 2026. PMID: 42782328. doi:10.1007/s00261-026-05802-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。